Indications and uses
Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.
Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.
INFANTS: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes). NOTE: L imited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective. CHILDREN AND ADULTS: 4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth...
SHAKE WELL BEFORE USE Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15° C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. AVOID FREEZING Pharmacists: Dispense in a tight, light-resistant container as defined in the USP. Distributed by: Kesin Pharma Oldsmar, FL 34677 Revised: 12/2025 PI-015B-V01
Nystatin is an antimycotic polyene antibiotic obtained from
Streptomyces noursei.
Structural formula:
Nystatin Oral Suspension, for oral administration, is cherry/mint flavored, containing 100,000 USP Nystatin Units per mL. Inactive ingredients: cherry flavor, dibasic sodium phosphate heptahydrate, disodium edetate, glycerin, methylparaben, monobasic sodium phosphate monohydrate, peppermint oil, propylparaben, sodium benzoate, sodium hexametaphosphate, and sucrose.
Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.
Nystatin is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi. Candida albicans demonstrates no significant resistance to nystatin in vitroon repeated subculture in increasing levelso f nystatin; other Candida species become quite resistant. Generally, resistance does not develop in vivo. Nystatin acts by binding to sterols in the cell membrane of susceptible Candida species with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.
Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.
The preparation is contraindicated in patients with a history of hypersensitivity to any of its components.
This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.
No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.
Animal reproduction studies have not been conducted with nystatin oral suspension. It is also not known whether nystatin oral suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin oral suspension should be given to a pregnant woman only if clearly needed.
It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.
See DOSAGE AND ADMINISTRATION.
Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported. (See PRECAUTIONS: General).
Gastrointestinal: Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.
Dermatologic: Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.
Other: Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been rarely reported.
To report SUSPECTED ADVERSE REACTIONS, contact Kesin Pharma at 1-833-537-4679 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (see CLINICAL PHARMACOLOGY, Pharmacokinetics).
INFANTS: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).
NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective.
CHILDREN AND ADULTS: 4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be retained in the mouth as long as possible before swallowing.
Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of Candida albicans.
Nystatin Oral Suspension, USP 100,000 USP Nystatin Units per mL, is available as a cherry-mint flavored, yellow, ready-to-use suspension, supplied in the following oral dosage forms:
NDC 81033-015-60: 60 mL bottle with a 1 mL calibrated dropper
NDC 81033-015-16: 16 oz (473 mL) bottle
Rx Only
SHAKE WELL BEFORE USE
Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15° C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
AVOID FREEZING
Pharmacists: Dispense in a tight, light-resistant container as defined in the USP.
Distributed by:
Kesin Pharma
Oldsmar, FL 34677
Revised: 12/2025
PI-015B-V01
Rx Only
NDC 81033- 015-16
Nystatin Oral Suspension, USP
SHAKE WELL BEFORE USING
Rx Only
NDC 81033- 015-60
Nystatin Oral Suspension, USP
SHAKE WELL BEFORE USING
Rx Only
NDC 81033- 015-60
Nystatin Oral Suspension, USP
SHAKE WELL BEFORE USING
(Includes safe cap dropper)
| Class | Version | Type | Effective |
|---|---|---|---|
| NYSTATIN Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| e29fe634-dc25-094c-c77f-5d09c3eceb3e | Product name | 5 | 20260107 |
| 726062af-1135-4707-a1d7-57256991bbf9 | Product name | 2 | 20250226 |
| e57b6340-9387-3f9a-7307-511c81791375 | Product name | 3 | 20221214 |
| 544f8e8d-6389-eeeb-9586-aa447c08dcc7 | Product name | 5 | 20210614 |
| 1629e00f-54fb-4a43-8306-b58442b23902 | Product name | 9 | 20200430 |
| 854ec07b-1cd7-a5db-235a-7aa24d3cf97a | Product name | 3 | 20180628 |
| 19b9f4c1-15e9-edcc-4c16-f01ecfb5c549 | Product name | 1 | 20140508 |
| 19c71a3d-ed9c-166b-a7e5-38c250c35631 | Product name | 1 | 20140508 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 81033-015-01 | ML - Milliliter | 81033-015 | 2cfb8a81-2eb0-4024-8476-284f8d063336 | 1 | 2026-03-17 |
| 81033-015-05 | ML - Milliliter | 81033-015 | 49867bf3-a8d3-4975-bb87-7df548767592 | 1 | 2026-03-17 |
| 81033-015-54 | ML - Milliliter | 81033-015 | 24ab3546-05de-4da6-a3a5-dadae4b1265b | 1 | 2026-03-17 |
| 85742-013-10 | ML - Milliliter | 85742-013 | 06ea4c79-8f02-4af6-8b21-1b9ff937980b | 1 | 2025-12-16 |
| 85742-013-11 | ML - Milliliter | 85742-013 | e963209c-0b03-4094-8082-9232670fbf5f | 1 | 2025-12-16 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 81033-015 | 81033-015-16, 81033-015-60 |
| 85742-013 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| EDETATE DISODIUM | 7FLD91C86K | IACT |
| SODIUM BENZOATE | OJ245FE5EU | IACT |
| HEXASODIUM HEXAMETAPHOSPHATE | N40N91DW96 | IACT |
| SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE | 70WT22SF4B | IACT |
| SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | 593YOG76RN | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| METHYLPARABEN | A2I8C7HI9T | IACT |
| PROPYLPARABEN | Z8IX2SC1OH | IACT |
| SUCROSE | C151H8M554 | IACT |
| PEPPERMINT OIL | AV092KU4JH | IACT |
| NYSTATIN | BDF1O1C72E | ACTIB |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A062832-001 | NYSTATIN | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 |
| Application-product | TE code |
|---|---|
| A062832-001 | AA |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | 1991-12-27 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | 1991-12-27 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | 1991-12-27 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | 1991-12-27 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | 1991-12-27 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | 1991-12-27 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | 1991-12-27 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | 1991-12-27 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | 1991-12-27 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | 1991-12-27 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | 1991-12-27 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | 3a93d1ddd44b… | |
| 2022-10-28 04:53 UTC | 2022-10 | A062832-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 1991-12-27 | f41ea6bd6efb… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A062832-001 | AA | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A062832-001 | AA | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A062832-001 | AA | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A062832-001 | AA | 1 | 31067a03dcf5… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A062832-001 | AA | 1 | 5bbf6a4d5a75… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A062832-001 | AA | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A062832-001 | AA | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A062832-001 | AA | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A062832-001 | AA | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A062832-001 | AA | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A062832-001 | AA | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A062832-001 | AA | 1 | 4b0b4de00fa7… |
| 2022-03-09 01:35 UTC | 2022-03 | A062832-001 | AA | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A062832-001 | AA | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A062832-001 | AA | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A062832-001 | AA | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A062832-001 | AA | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A062832-001 | AA | 1 | c0c555d07b60… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A062832-001 | AA | 1 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | A062832-001 | AA | 1 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | A062832-001 | AA | 1 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A062832-001 | AA | 1 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A062832-001 | AA | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A062832-001 | AA | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A062832-001 | AA | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | A062832-001 | AA | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | A062832-001 | AA | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A062832-001 | AA | 1 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | A062832-001 | AA | 1 | f41ea6bd6efb… |
| 2022-09-29 23:25 UTC | 2022-09 | A062832-001 | AA | 1 | e64feba35796… |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A062832-001 | AA | 1 | cb3db0bc1861… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A062832-001 | AA | 1 | a50c72e98297… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| NYSTATIN | NYSTATIN | Kesin Pharma Corporation | 50737729-a4a4-e747-e063-6394a90adcc5 | 2026-06-30 | Adverse reactions | 81033-015-60 81033-015-16 81033-015 81033001560 81033001516 50738a43-7297-270c-e063-6294a90af2cc 50737729-a4a4-e747-e063-6394a90adcc5 |
| NYSTATIN | NYSTATIN | Kesin Pharma Corporation | 43817169-bbe8-58ee-e063-6294a90a1250 | 2025-12-11 | Adverse reactions | 81033-015 |
| NYSTATIN | NYSTATIN | Kanchan Healthcare Inc | 90a52c3f-3ef7-4f3b-9fe5-40af408e9f2a | 2025-09-12 | Adverse reactions | 85742-013 |
Adverse event summaries are temporarily unavailable. Other product information remains available.